Dr Reddys Net Worth

Dr Reddys Net Worth Breakdown

  RDY
The net worth of Dr Reddys Laboratories is the difference between its total assets and liabilities. Dr Reddys' net worth represents the value of the company's equity or ownership interest. In other words, it is the amount of money that would be left over if all of Dr Reddys' assets were sold and all of its debts were paid off. Net worth is sometimes referred to as shareholder's equity or book value. Dr Reddys' net worth can be used as a measure of its financial health and stability which can help investors to decide if Dr Reddys is a good investment. It is also essential in determining the company's creditworthiness and ability to secure financing before investing in Dr Reddys Laboratories stock.

Dr Reddys Net Worth Analysis

Dr Reddys' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Dr Reddys' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Dr Reddys' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Dr Reddys' net worth analysis. One common approach is to calculate Dr Reddys' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Dr Reddys' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Dr Reddys' net worth. This approach calculates the present value of Dr Reddys' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Dr Reddys' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Dr Reddys' net worth. This involves comparing Dr Reddys' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Dr Reddys' net worth relative to its peers.

Enterprise Value

1.11 Trillion

To determine if Dr Reddys is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Dr Reddys' net worth research are outlined below:
Dr Reddys generated a negative expected return over the last 90 days
Latest headline from insidermonkey.com: Jim Cramer on IDEXX Laboratories Is This Pet Stock Poised for a Comeback

Dr Reddys Quarterly Good Will

11.77 Billion

Dr Reddys uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Dr Reddys Laboratories. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Dr Reddys' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
31st of January 2024
Upcoming Quarterly Report
View
8th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
8th of May 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of March 2023
Last Financial Announcement
View

Know Dr Reddys' Top Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Dr Reddys is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Dr Reddys Laboratories backward and forwards among themselves. Dr Reddys' institutional investor refers to the entity that pools money to purchase Dr Reddys' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares
Jpmorgan Chase & Co2024-09-30
500.7 K
Fisher Asset Management, Llc2024-09-30
491.3 K
Gqg Partners Llc2024-09-30
437 K
Bnp Paribas Arbitrage, Sa2024-09-30
409.4 K
Healthcare Of Ontario Pension Plan Trust Fund2024-09-30
343.8 K
Jane Street Group Llc2024-06-30
291.8 K
Man Group Plc2024-09-30
208.5 K
Wellington Management Company Llp2024-09-30
168.5 K
Lazard Asset Management Llc2024-09-30
167.9 K
Morgan Stanley - Brokerage Accounts2024-09-30
2.2 M
Robeco Institutional Asset Management Bv2024-09-30
2.1 M
Note, although Dr Reddys' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Follow Dr Reddys' market capitalization trends

The company currently falls under 'Large-Cap' category with a total capitalization of 13.11 B.

Market Cap

1.09 Trillion

Project Dr Reddys' profitablity

Last ReportedProjected for Next Year
Return On Tangible Assets 0.16  0.11 
Return On Capital Employed 0.23  0.24 
Return On Assets 0.14  0.15 
Return On Equity 0.20  0.10 
The company has Net Profit Margin of 0.18 %, which implies that it may need a different competitive strategy as even a very small decline in it revenue may erase profits and result in a net loss. This is way below average. In the same way, it shows Net Operating Margin of 0.23 %, which entails that for every 100 dollars of revenue, it generated $0.23 of operating income.
When accessing Dr Reddys' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Dr Reddys' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Dr Reddys' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Dr Reddys' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Dr Reddys Laboratories. Check Dr Reddys' Beneish M Score to see the likelihood of Dr Reddys' management manipulating its earnings.

Evaluate Dr Reddys' management efficiency

Dr Reddys Laboratories has Return on Asset of 0.104 % which means that on every $100 spent on assets, it made $0.104 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.1927 %, implying that it generated $0.1927 on every 100 dollars invested. Dr Reddys' management efficiency ratios could be used to measure how well Dr Reddys manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Dr Reddys' Return On Capital Employed is fairly stable compared to the past year. Return On Assets is likely to rise to 0.15 in 2024, whereas Return On Tangible Assets are likely to drop 0.11 in 2024. At this time, Dr Reddys' Other Assets are fairly stable compared to the past year. Non Currrent Assets Other is likely to rise to about 16.9 B in 2024, whereas Total Assets are likely to drop slightly above 214.9 B in 2024.
Last ReportedProjected for Next Year
Book Value Per Share 337.21  527.34 
Tangible Book Value Per Share 287.69  392.73 
Enterprise Value Over EBITDA 11.93  12.52 
Price Book Value Ratio 3.71  3.89 
Enterprise Value Multiple 11.93  12.52 
Price Fair Value 3.71  3.89 
Enterprise Value1.1 T1.1 T
Management at Dr Reddys Laboratories focuses on leveraging technology and optimizing operations. We evaluate the impact of these focuses on the company's financial health and stock performance.
Enterprise Value Revenue
3.6811
Revenue
299.9 B
Quarterly Revenue Growth
0.165
Revenue Per Share
60.1437
Return On Equity
0.1927

Dr Reddys Corporate Filings

6K
20th of December 2024
A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges.
ViewVerify
13A
24th of October 2024
The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934
ViewVerify
23rd of October 2024
Other Reports
ViewVerify
Dr Reddys time-series forecasting models is one of many Dr Reddys' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Dr Reddys' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Dr Reddys Earnings per Share Projection vs Actual

Dr Reddys Corporate Directors

Leo PuriNon-Executive Independent DirectorProfile
Arunabha RayChaudhuriHead DirectorProfile
Prasad MenonLead Non-Executive Independent DirectorProfile
Shikha SharmaNon-Executive Independent DirectorProfile

Additional Tools for RDY Stock Analysis

When running Dr Reddys' price analysis, check to measure Dr Reddys' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Dr Reddys is operating at the current time. Most of Dr Reddys' value examination focuses on studying past and present price action to predict the probability of Dr Reddys' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Dr Reddys' price. Additionally, you may evaluate how the addition of Dr Reddys to your portfolios can decrease your overall portfolio volatility.